OCULAR THERAPEUTIX, INC (OCUL)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, OCULAR THERAPEUTIX, INC reported revenue of $51.95M, down 18.5% from the prior year. The company ran a net loss, with a net margin of -511.9%. It held $808.06M in total assets against $153.75M in total liabilities.
Key ratios (FY2025)
-519.8%
Operating margin
-511.9%
Net margin
-40.6%
Return on equity
-18.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M | $17.40M | $4.23M | $1.99M | $1.92M | — |
| Cost of Revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M | $2.08M | $2.33M | $465.0K | $457.0K | — |
| Operating Income | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M | -$62.85M | -$85.80M | -$59.12M | -$61.92M | -$43.33M |
| Net Income | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M | -$155.64M | -$86.37M | -$59.98M | -$63.39M | -$44.70M |
| EPS (Diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | — | — | — |
| Total Assets | $808.06M | $457.94M | $252.06M | $149.29M | $204.89M | $261.86M | $78.74M | $73.04M | $55.43M | $74.94M |
| Total Liabilities | $153.75M | $142.59M | $160.93M | $113.91M | $116.89M | $185.77M | $82.37M | $37.17M | $29.28M | $22.93M |
| Shareholders' Equity | $654.31M | $315.34M | $91.13M | $35.38M | $88.00M | $76.09M | -$3.63M | $35.88M | $26.15M | $52.01M |
| Cash & Equivalents | $737.06M | $392.10M | $195.81M | $102.30M | $164.16M | $228.06M | $54.44M | $54.06M | $41.54M | $32.94M |
| Operating Cash Flow | -$204.88M | -$134.68M | -$70.23M | -$59.60M | -$65.55M | -$53.55M | -$77.58M | -$49.23M | -$50.47M | -$34.00M |
| Capital Expenditures | $12.01M | $1.29M | $6.09M | $3.71M | $1.19M | $841.0K | $2.24M | $1.89M | $8.25M | $1.92M |
| Shares Outstanding | 215.93M | 157.75M | 114.96M | 77.20M | 76.73M | 76.00M | 50.33M | 41.52M | 29.66M | 25.02M |